Safety and efficacy of ViaNautis polyNaut® candidates V.1

• Research type

  Research Study

• Full title

  In vitro analysis of efficacy and/or safety of ViaNautis polyNaut® nanovesicles to select best candidates to take forward to in vivo pre-clinical and clinical studies v1.

• IRAS ID

  365122

• Contact name

  Sarah Wythe

• Contact email

  sarah.wythe@vianautis.com

• Sponsor organisation

  ViaNautis Bio Ltd

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  2 years, 0 months, 1 days

• Research summary

  ViaNautis polyNaut® technology consists of nanovesicles displaying cell-specific targeting properties. The aim of this research is to assess the targeting capabilities of our nanovesicles in primary immune cells and the impact of targeting on cell viability. Samples used in this research would not be introduced back into patients. Specific questions to be answered include:

  • Can polyNaut® nanovesicles target specific subsets of immune cells

  • Can polyNaut® nanovesicles safely deliver fluorescent reporters and therapeutic proteins to target cells.

• REC name

  HSC REC A

• REC reference

  26/NI/0034

• Date of REC Opinion

  3 Mar 2026

• REC opinion

  Favourable Opinion